Nektar Therapeutics (NKTR) has presented new clinical data for its lead asset, rezpegaldesleukin, to dermatology specialists at the 2026 EADV Congress, highlighting long-term outcomes in atopic dermatitis and alopecia areata.
Despite the fresh rezpegaldesleukin data, Nektar Therapeutics' recent share price action has been choppy, with the stock down about 41% on a 1 month share price return and down around 39% on a 3 month share price return. At the same time, the 3 year total shareholder return is very large, while the 5 year total shareholder return shows a steep decline of about 83%, suggesting long term momentum has faded after an earlier surge.
Scan beyond Nektar Therapeutics and explore other potential breakout drug developers in our hand-picked list of 20 high quality undiscovered gems
Nektar Therapeutics now sits in an awkward spot. Recent rezpegaldesleukin data are strong, while the share price has already fallen hard. Has most of the easy upside already played out, or is the market still underpricing it?
Most Popular Narrative: 71% Undervalued
The most followed narrative puts Nektar Therapeutics' fair value at $144.40 per share, well above the recent close near $41.17. This frames the rezpegaldesleukin story as a long runway opportunity rather than a short term trade.
Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk. This supports earnings predictability and reduces financial leverage concerns.
Broadening of pipeline applications (e.g., immunology, autoimmune, dermatology) and the prospect of international partnerships or strategic out-licensing align with the global expansion of healthcare access. This provides opportunities for diversified and growing revenue streams in coming years.
See why 13 investors see Nektar Therapeutics as 71% undervalued .
Result: Fair Value of $144.40 (UNDERVALUED)
Still, the whole setup around Nektar Therapeutics can change quickly if rezpegaldesleukin stumbles in late stage trials or if funding becomes more expensive and harder to secure.
Find out about the key risks to this Nektar Therapeutics narrative .
Another View: Nektar Therapeutics Looks Expensive On Sales
Nektar Therapeutics might screen as 71% undervalued against that $144.40 fair value, yet its current P/S ratio of 25.8x paints a very different picture. The broader US Biotechs group trades around 12.2x, while the fair ratio model points to 9.7x, which suggests valuation risk rather than a clear bargain.
If the share price ever moved closer to that 9.7x fair ratio, investors would be dealing with a very different outcome to the bullish narrative. The question is whether you think the rezpegaldesleukin story is strong enough to justify paying more than peers and the fair ratio for every dollar of forecast revenue.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages on Nektar Therapeutics so far. If you want to move fast and rely on your own judgment, start with the balance of 1 key reward and 3 important warning signs
Looking for more Nektar Therapeutics investment ideas?
If Nektar Therapeutics has your attention, do not stop with a single ticker. Use screeners to surface fresh opportunities before they move without you.
-
Target potential value opportunities early by scanning the 29 high quality undervalued stocks that pair quality fundamentals with compressed market expectations.
-
Prioritise resilience by checking the 31 resilient stocks with low risk scores that combine sturdier balance sheets with fewer red flags in the risk profile.
-
Go beyond widely followed tickers and review the 20 high quality undiscovered gems that may not yet be fully reflected in market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NKTR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
